Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of gout
3.2.1.2 Advancements in treatment options
3.2.1.3 Rising awareness towards early gout diagnosis
3.2.1.4 Dietary and lifestyle shifts
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of gout treatment
3.2.2.2 Side effects & safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
5.3 Corticosteroids
5.4 Colchicine
5.5 Urate-lowering agents
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Condition, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Acute gout
6.3 Chronic gout
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astrazeneca Plc
10.2 Addex Therapeutics
10.3 Abbvie Inc.
10.4 Amgen Inc.
10.5 Boehringer Ingelheim International GmbH
10.6 GSK plc
10.7 Merck & Co., Inc
10.8 Novartis AG
10.9 Pfizer Inc
10.10 Regeneron Pharmaceuticals, Inc.
10.11 Sun Pharmaceutical Industries Ltd.
10.12 Takeda Pharmaceutical Company Ltd.
10.13 Teva Pharmaceuticals Industries Ltd.
10.14 Teijin Limited
10.15 Zydus Lifesciences Limited
